EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Encoded metabolic remodeling amplifies drug resistance in Mycobacterium tuberculosis

Abigail M Frey iD, Gregory H Babunovic, Peter H Culviner, Xin Wang, Ella Meirav, Mingyu Gan, Junhao Zhu, D Branch Moody, Qingyun Liu, Sarah M Fortune iD

PLOS Pathogens · 2026

DOI: 10.1371/journal.ppat.1014237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Abigail M Frey und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Drug Resistance, Bacterial, Bacterial Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Science Foundation Graduate Research Fellowship Program, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic pressure causes pathogens to evolve many forms of altered drug susceptibility. In addition to target or activator mutations conferring canonical drug resistance, mutations can serve as steppingstones to or enhancers of resistance. In clinical strains of Mycobacterium tuberculosis (Mtb), we find that idsA2, which encodes an isoprenyl pyrophosphate synthase involved in the synthesis of precursors for essential components of the cell wall and electron transport chain, is undergoing diversifying selection in Lineage 4, and that these mutations are associated with the acquisition of first-line antibiotic resistance. By engineering isogenic Mtb strains to express clinically prevalent variants of idsA2 , we show that idsA2 variants alter the inhibitory concentrations of first-line drugs, most significantly increasing the inhibitory concentration of ethambutol by two-fold. Targeted lipid analyses reveal that disrupting IdsA2 function redirects limited resources in the isoprenoid synthesis pathway, leading to increased production of decaprenyl phosphate species. This suggests that idsA2 and ubiA mutations share an ethambutol resistance mechanism. Where idsA2 mutations arise after embB mutations, they maintain their multiplicative effect on the inhibitory concentration of ethambutol such that the variants together result in high-level resistance. As a result, identification of idsA2 mutations can be utilized to improve the specificity of genotypic ethambutol susceptibility testing. Together, this work shows how idsA2 mutations remodel bacterial metabolism and augment ethambutol resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsDrug Resistance, BacterialBacterial ProteinsMutationEthambutolMicrobial Sensitivity TestsHumans

Substanzen

Antitubercular AgentsBacterial ProteinsEthambutol

Autor:innen und Institutionen

  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Abigail M Frey, Sarah M Fortune

Förderung

  • NIAID NIH HHS
  • National Science Foundation Graduate Research Fellowship Program
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Frey, A. M., Babunovic, G. H., Culviner, P. H., Wang, X., Meirav, E., Gan, M., Zhu, J., Moody, D. B., Liu, Q., & Fortune, S. M. (2026). Encoded metabolic remodeling amplifies drug resistance in Mycobacterium tuberculosis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014237

Vancouver

Frey AM, Babunovic GH, Culviner PH, Wang X, Meirav E, Gan M, et al. Encoded metabolic remodeling amplifies drug resistance in Mycobacterium tuberculosis. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014237

BibTeX
@article{Frey2026,
  author = {Frey, Abigail M and Babunovic, Gregory H and Culviner, Peter H and Wang, Xin and Meirav, Ella and Gan, Mingyu and Zhu, Junhao and Moody, D Branch and Liu, Qingyun and Fortune, Sarah M},
  title = {Encoded metabolic remodeling amplifies drug resistance in Mycobacterium tuberculosis},
  journal = {PLOS Pathogens},
  year = {2026},
  doi = {10.1371/journal.ppat.1014237}
}
Kostenlos starten →